Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label Study to Evaluate the Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adult Participants Followed by a Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Immunogenicity and Safety of Hecolin® in Children

NCT06306196 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT06306196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06306196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label Study to Evaluate the Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adult Participants Followed by a Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Immunogenicity and Safety of Hecolin® in Children
Lead sponsor
International Vaccine Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 4, 2024
Completion date
January 31, 2026
Enrollment
1,040 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis e virus infection